Clinical expenses rose by $11.1 million at NewAmsterdam Pharma in the three months ended June 30, as the company started new trials and advanced existing ones. The awkward arithmetic: revenue fell 80.7% to $3.7 million from $19.1 million in the comparable period.
That makes the latest report less a simple decline in activity than a clash between lumpy license revenue and a steadily expanding clinical bill. Research and development spending climbed 51.5% to $41.7 million, while the net loss widened to $64.1 million from $17.4 million.
NewAmsterdam said the biggest expense increase came from clinical work, but the comparison was also unusually favorable a year earlier because some trials were being closed out and generated credits.
"This was primarily driven by: an $11.1 million increase in clinical expenses mainly due to the initiation of clinical trials and increased costs associated with the progression of ongoing trials, as well as credits received upon the close-out of trials in the comparative period that did not recur in the current period; a $3.3 million increase in personnel expenses related to research and development activities, including the impact of including medical affairs related personnel costs in the current period, as discussed above."
NewAmsterdam Pharma, 10-Q filed Aug. 5, 2026
The company is therefore spending more on the pipeline while the income statement gets less help from the licensing line. Operating losses reached $64.9 million, and cash fell to $424.2 million from $563.9 million a year earlier. Diluted shares also rose 4.1% to 123.4 million.
The revenue decline has a similarly specific explanation. NewAmsterdam disclosed that the comparable period included a $16.1 million installment tied to development cost contributions under its Menarini license.
"This decrease was largely due to the recognition of $16.1 million of revenue related to the second installment of development cost contributions under the Menarini License in the comparative period."
NewAmsterdam Pharma, 10-Q filed Aug. 5, 2026
That installment was not repeated in the current three months. The report also says milestone payments are not initially recognized because commercialization depends on clinical-trial success, which leaves revenue timing tied to scientific and regulatory events rather than to a smooth sales curve.
The balance between those two lines matters because NewAmsterdam is still a development-stage business. Its 2025 revenue was $22.5 million, against an enterprise value of $2.8 billion, or 123.1 times that annual revenue. The multiple is a mechanical snapshot, not a forecast, but it shows why the accounting timing matters: a single license installment can dwarf a normal reporting period.
The cash-flow picture points in the same direction. Free cash flow margin fell to -1037.5%, and capital spending consumed more revenue than in the comparable period. The 10-Q attributes the cash-flow change primarily to favorable working-capital movements, including lower prepayments and receivables, partly offset by higher operating expenses. It does not turn that into a recurring source of funding.
NewAmsterdam’s next quarterly report should make the comparison more legible by showing whether license-related revenue returns alongside the clinical spending, or whether the business is still carrying a larger research bill without another installment. For now, the trade-off is plain: less revenue on the page, more trial work off it.
Source: NewAmsterdam Pharma’s 10-Q filed Aug. 5, 2026, for the three months ended June 30, 2026.